前列地尔注射液联合血浆置换治疗重型肝炎33例

Prostaglandin E1 combined with plasma exchange for treatment of patients with severe hepatitis:an analysis of 33 cases

目的:评价前列地尔注射液联合血浆置换治疗重型肝炎的疗效.方法:将62例重型肝炎患者随机分为试验组和对照组.试验组33例(亚急性重型肝炎2例,慢性重型肝炎31例)在内科综合治疗基础上加用血浆置换及前列地尔注射液;对照组29例(亚急性重型肝炎1例,慢性重型肝炎28例)仅用内科综合治疗加用血浆置换.结果:试验组和对照组治疗后,各指标均有明显改善,与本组治疗前比较,差异均有显著性(P<0.01):试验组治疗后TBIL和PTA改善更为明显,与对照组比较差异均有显著性(155.8±138.2 umol/L vs 296.4±100.5 umol/L,62.6%±10.4%vs 42.9%±11.4%;P<0.01);试验组存活率(治愈及好转)显著优于对照组(72.8%vs 48.3%.P<0.01).结论:前列地尔注射液联合血浆置换是治疗重型肝炎的有效方法.

AIM： To evaluate the therapeutic effects of prostaglandin E1 （PGE1） combined with plasma exchange in patients with severe hepatitis. METHODS： Sixty-two patients with severe hepatitis were randomly divided into treatment （n = 33） and control （n = 29） groups. In the treat- ment group, 33 patients with severe hepatitis （two with subacute severe hepatitis, and 31 with chronic severe hepatitis） received combined therapy with comprehensive internal medicine treatment which was the artificial liver support system and PGE1. In the control group, 29 patients （one with subacute severe hepatitis, and 28 with chronic severe hepatitis） were treated with comprehensive internal medicine and the artificial liver support system. RESULTS： After treatment, serum total bilirubin, alanine aminotransferase, and PTA were significantly improved in the two groups. There were significant differences between the treatment and control group in concentration of TBIL and PTA （155.8 ± 138.2 μmol/L vs 296.4 ± 100.5 μmol/L; 62.6% ± 10.4% vs 42.9% ±11.4%; P 〈 0.01）. The survival rate in the treatment group was higher than that in the control group （72.8% vs 48.3%, P 〈 0.01）. CONCLUSION： PGE1 combined with plasma exchange is an effective method for treating severe hepatitis.